SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001169245-21-000095
Filing Date
2021-09-15
Accepted
2021-09-15 08:04:59
Documents
14
Period of Report
2021-09-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K phas-20210914.htm   iXBRL 8-K 47638
2 EX-99.1 phasebioboardcompositionch.htm EX-99.1 13756
6 GRAPHIC image_0.jpg GRAPHIC 914863
  Complete submission text file 0001169245-21-000095.txt   1430943

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20210914.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20210914_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20210914_pre.xml EX-101.PRE 13731
7 EXTRACTED XBRL INSTANCE DOCUMENT phas-20210914_htm.xml XML 11630
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

IRS No.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 211254293
SIC: 2834 Pharmaceutical Preparations